The maximum tolerated dose has not yet been determined. Pharmacokinetics: Early pharmacokinetic data indicate a median half-life of approximately seven days, potentially enabling bi-weekly dosing.
The company's bi-weekly newsletter will provide updates on new additions to the marketplace throughout the event period.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback